Placement
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Syntara Limited has announced a placement to raise funds for clinical trials and drug development, receiving strong support from investors. The funds will support various clinical trials and general working capital needs. Syntara's CEO expressed gratitude for the investor support following positive interim results from a recent study.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/placement-19
In the deck
Earlier from Syntara
- Interim data in Phase 2 study of SNT-5505 in myelofibrosis
- Presentation: Phase 2 study of SNT-5505 in myelofibrosis
- Trading Halt
- Response to ASX Price Query
- Pause in Trading
Later from Syntara
- Acceleration of skin scarring program
- Quarterly Activities Report
- SNT-5505 awarded US FDA Fast Track designation
- New positive interim data in Phase 2 study of SNT-5505
- Quarterly Shareholder Report
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara